Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07422675 | SAD Study in Patients With Parkinson's Disease and Motor Fluctuations | PHASE1 | RECRUITING | 40 | — | — | Jan 1, 2026 | Jan 1, 2027 | Mar 2, 2026 | - | — |
| Name | Type | Description |
|---|---|---|
| SER-252 (PEOZ-apomorphine) | DRUG | SER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% trehalose to maintain final pH and isotonicity in the reconstituted product. |
| enFuse | DEVICE | The enFuse® device is a sterile, non-pyrogenic, user-filled, single-use, fixed-dose subcutaneous dose delivery system. |